A real-time PCR assay for the detection of varicella-zoster virus DNA and differentiation of vaccine, wild-type and control strains

Journal of Virological Methods

Volumn 113, Issue 2, 2003, Pages 113-116

  Tipples, Graham A ^a   Safronetz, David ^a   Gray, Michael ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Chickenpox; LightCycler; Shingles

Indexed keywords

LIVE VACCINE; VARICELLA ZOSTER VACCINE; VIRUS DNA;

ARTICLE; ASSAY; BIOLOGICAL WARFARE; CONTROLLED STUDY; DNA DETERMINATION; DNA PROBE; HYBRIDIZATION; LABORATORY TEST; NONHUMAN; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION SITE; SMALLPOX; STRAIN DIFFERENCE; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS STRAIN; WILD TYPE;

HUMAN HERPESVIRUS 3; VARIOLA VIRUS;

EID: 0141671894     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(03)00229-5     Document Type: Article

References (16)

1. Argaw T., Cohen J.I., Klutch M., Lekstrom K., Yoshikawa T., Asano Y., Krause P.R. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. J. Infect. Dis. 181:2000;1153-1157.
2. Centers for Disease Control, 1996. Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). MMWR 45, 1-36.
3. Gail K., Lee B., Shrine T., Carraher C., Baughman A.L., Eaton M., Montero L., Steward J. Outbreak of varicella at a day-care center despite vaccination. N. Engl. J. Med. 347:2002;1909-1915.
4. Hawrami K., Breuer J. Analysis of United Kingdom wild-type strains of varicella-zoster virus: differentiation from Oka vaccine strain. J. Med. Virol. 53:1997;60-62.
5. Health Canada, 1999. National committee on immunization statement on recommended use of varicella virus vaccine. Can. Commun. Dis. Rep. 25, 1-16.
6. LaRussa P., Lungu O., Hardy I., Gershon A., Steinberg S.P., Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J. Virol. 66:1992;1016-1020.
7. Liang M.G., Heidelberg K.A., Jacobson R.M., McEvoy M.T. Herpes zoster after varicella immunization. J. Am. Acad. Dermatol. 38:1998;761-763.
8. Loparev V.N., Argaw T., Krause P.R., Takayama M., Schmid D.S. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J. Clin. Microbiol. 38:2000a;3156-3160.
9. Loparev V.N., McCaustland K., Holloway B.P., Krause P.R., Takayama M., Schimd D.S. Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes. J. Clin. Microbiol. 38:2000b;4315-4319.
10. Martin J.H., Dohner D.E., Wellinghoff W.J., Gelb L.D. Restriction endonuclease analysis of varicella-zoster vaccine virus and wild-type DNAs. J. Med. Virol. 9:1982;69-72.
11. Safronetz D., Humar A., Tipples G.A. Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. J. Virol. Methods. 112:2003;99-105.
12. Shiraki K., Horiuchi K., Asano Y., Yamanishi K., Takahashi M. Differentiation of Oka vaccine strain from wild varicella-zoster virus strains isolated from vaccines and household contact. J. Med. Virol. 33:1991;128-132.
13. Takahashi, M., Plotkin, S.A., 2000. Development of the Oka vaccine. In: Arvin, A.M., Gershon, A.A. (Eds.), Varicella-Zoster Virus: Virology and Clinical Management. Cambridge University Press, Cambridge, UK, pp. 442-459.
14. Tipples G.A., Stephens G.M., Sherlock C., Bowler M., Hoy B., Cook D., Grose C. A new variant of varicella-zoster virus. Emerg. Infect. Dis. 8:2002;1504-1505.
15. White C.J. Clinical trials of varicella vaccine in healthy children. Infect. Dis. Clin. N. Am. 10:1996;595-608.
16. White C.J. Varicella zoster virus vaccine. Clin. Infect. Dis. 24:1997;753-763.